NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer

Results from the Spanish Bladder Cancer Study and meta-analyses

Montserrat García-Closas, Núria Malats, Debra Silverman, Mustafa Dosemeci, Manolis Kogevinas, David W. Hein, Adonina Tardón, Consol Serra, Alfredo Carrato, Reina García-Closas, Josep Lloreta, Gemma Castaño-Vinyals, Meredith Yeager, Robert Welch, Stephen Chanock, Nilanjan Chatterjee, Sholom Wacholder, Claudine Samanic, Montserrat Torà, Francisco Fernández & 2 others Francisco X. Real, Nathaniel Rothman

Research output: Contribution to journalArticle

Abstract

Background: Many reported associations between common genetic polymorphisms and complex diseases have not been confirmed in subsequent studies. An exception could be the association between NAT2 slow acetylation, GSTM1 null genotype, and bladder-cancer risk. However, current evidence is based on meta-analyses of relatively small studies (range 23-374 cases) with some evidence of publication bias and study heterogeneity. Associations between polymorphisms in other NAT and GST genes and bladder-cancer risk have been inconsistent. Methods: We investigated polymorphisms in NAT2, GSTM1, NAT1, GSTT1, GSTM3, and GSTP1 in 1150 patients with transitional-cell carcinoma of the urinary bladder and 1149 controls in Spain; all the participants were white. We also carried out meta-analyses of NAT2, GSTM1, and bladder cancer that included more than twice as many cases as in previous reports. Findings: In our study, the odds ratios for bladder cancer for individuals with deletion of one or two copies of the GSTM1 gene were 1.2 (95% CI 0.8-1.7) and 1.9 (1.4-2.7) respectively (p for trend

Original languageEnglish (US)
Pages (from-to)649-659
Number of pages11
JournalThe Lancet
Volume366
Issue number9486
DOIs
StatePublished - Aug 20 2005
Externally publishedYes

Fingerprint

Acetylation
Urinary Bladder Neoplasms
Meta-Analysis
Genotype
Publication Bias
Transitional Cell Carcinoma
Genetic Polymorphisms
Spain
Genes
Urinary Bladder
Odds Ratio

ASJC Scopus subject areas

  • Medicine(all)

Cite this

García-Closas, M., Malats, N., Silverman, D., Dosemeci, M., Kogevinas, M., Hein, D. W., ... Rothman, N. (2005). NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. The Lancet, 366(9486), 649-659. https://doi.org/10.1016/S0140-6736(05)67137-1

NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer : Results from the Spanish Bladder Cancer Study and meta-analyses. / García-Closas, Montserrat; Malats, Núria; Silverman, Debra; Dosemeci, Mustafa; Kogevinas, Manolis; Hein, David W.; Tardón, Adonina; Serra, Consol; Carrato, Alfredo; García-Closas, Reina; Lloreta, Josep; Castaño-Vinyals, Gemma; Yeager, Meredith; Welch, Robert; Chanock, Stephen; Chatterjee, Nilanjan; Wacholder, Sholom; Samanic, Claudine; Torà, Montserrat; Fernández, Francisco; Real, Francisco X.; Rothman, Nathaniel.

In: The Lancet, Vol. 366, No. 9486, 20.08.2005, p. 649-659.

Research output: Contribution to journalArticle

García-Closas, M, Malats, N, Silverman, D, Dosemeci, M, Kogevinas, M, Hein, DW, Tardón, A, Serra, C, Carrato, A, García-Closas, R, Lloreta, J, Castaño-Vinyals, G, Yeager, M, Welch, R, Chanock, S, Chatterjee, N, Wacholder, S, Samanic, C, Torà, M, Fernández, F, Real, FX & Rothman, N 2005, 'NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses', The Lancet, vol. 366, no. 9486, pp. 649-659. https://doi.org/10.1016/S0140-6736(05)67137-1
García-Closas, Montserrat ; Malats, Núria ; Silverman, Debra ; Dosemeci, Mustafa ; Kogevinas, Manolis ; Hein, David W. ; Tardón, Adonina ; Serra, Consol ; Carrato, Alfredo ; García-Closas, Reina ; Lloreta, Josep ; Castaño-Vinyals, Gemma ; Yeager, Meredith ; Welch, Robert ; Chanock, Stephen ; Chatterjee, Nilanjan ; Wacholder, Sholom ; Samanic, Claudine ; Torà, Montserrat ; Fernández, Francisco ; Real, Francisco X. ; Rothman, Nathaniel. / NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer : Results from the Spanish Bladder Cancer Study and meta-analyses. In: The Lancet. 2005 ; Vol. 366, No. 9486. pp. 649-659.
@article{c52d5749c9aa4341b24cb5064fb0cf4a,
title = "NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses",
abstract = "Background: Many reported associations between common genetic polymorphisms and complex diseases have not been confirmed in subsequent studies. An exception could be the association between NAT2 slow acetylation, GSTM1 null genotype, and bladder-cancer risk. However, current evidence is based on meta-analyses of relatively small studies (range 23-374 cases) with some evidence of publication bias and study heterogeneity. Associations between polymorphisms in other NAT and GST genes and bladder-cancer risk have been inconsistent. Methods: We investigated polymorphisms in NAT2, GSTM1, NAT1, GSTT1, GSTM3, and GSTP1 in 1150 patients with transitional-cell carcinoma of the urinary bladder and 1149 controls in Spain; all the participants were white. We also carried out meta-analyses of NAT2, GSTM1, and bladder cancer that included more than twice as many cases as in previous reports. Findings: In our study, the odds ratios for bladder cancer for individuals with deletion of one or two copies of the GSTM1 gene were 1.2 (95{\%} CI 0.8-1.7) and 1.9 (1.4-2.7) respectively (p for trend",
author = "Montserrat Garc{\'i}a-Closas and N{\'u}ria Malats and Debra Silverman and Mustafa Dosemeci and Manolis Kogevinas and Hein, {David W.} and Adonina Tard{\'o}n and Consol Serra and Alfredo Carrato and Reina Garc{\'i}a-Closas and Josep Lloreta and Gemma Casta{\~n}o-Vinyals and Meredith Yeager and Robert Welch and Stephen Chanock and Nilanjan Chatterjee and Sholom Wacholder and Claudine Samanic and Montserrat Tor{\`a} and Francisco Fern{\'a}ndez and Real, {Francisco X.} and Nathaniel Rothman",
year = "2005",
month = "8",
day = "20",
doi = "10.1016/S0140-6736(05)67137-1",
language = "English (US)",
volume = "366",
pages = "649--659",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9486",

}

TY - JOUR

T1 - NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer

T2 - Results from the Spanish Bladder Cancer Study and meta-analyses

AU - García-Closas, Montserrat

AU - Malats, Núria

AU - Silverman, Debra

AU - Dosemeci, Mustafa

AU - Kogevinas, Manolis

AU - Hein, David W.

AU - Tardón, Adonina

AU - Serra, Consol

AU - Carrato, Alfredo

AU - García-Closas, Reina

AU - Lloreta, Josep

AU - Castaño-Vinyals, Gemma

AU - Yeager, Meredith

AU - Welch, Robert

AU - Chanock, Stephen

AU - Chatterjee, Nilanjan

AU - Wacholder, Sholom

AU - Samanic, Claudine

AU - Torà, Montserrat

AU - Fernández, Francisco

AU - Real, Francisco X.

AU - Rothman, Nathaniel

PY - 2005/8/20

Y1 - 2005/8/20

N2 - Background: Many reported associations between common genetic polymorphisms and complex diseases have not been confirmed in subsequent studies. An exception could be the association between NAT2 slow acetylation, GSTM1 null genotype, and bladder-cancer risk. However, current evidence is based on meta-analyses of relatively small studies (range 23-374 cases) with some evidence of publication bias and study heterogeneity. Associations between polymorphisms in other NAT and GST genes and bladder-cancer risk have been inconsistent. Methods: We investigated polymorphisms in NAT2, GSTM1, NAT1, GSTT1, GSTM3, and GSTP1 in 1150 patients with transitional-cell carcinoma of the urinary bladder and 1149 controls in Spain; all the participants were white. We also carried out meta-analyses of NAT2, GSTM1, and bladder cancer that included more than twice as many cases as in previous reports. Findings: In our study, the odds ratios for bladder cancer for individuals with deletion of one or two copies of the GSTM1 gene were 1.2 (95% CI 0.8-1.7) and 1.9 (1.4-2.7) respectively (p for trend

AB - Background: Many reported associations between common genetic polymorphisms and complex diseases have not been confirmed in subsequent studies. An exception could be the association between NAT2 slow acetylation, GSTM1 null genotype, and bladder-cancer risk. However, current evidence is based on meta-analyses of relatively small studies (range 23-374 cases) with some evidence of publication bias and study heterogeneity. Associations between polymorphisms in other NAT and GST genes and bladder-cancer risk have been inconsistent. Methods: We investigated polymorphisms in NAT2, GSTM1, NAT1, GSTT1, GSTM3, and GSTP1 in 1150 patients with transitional-cell carcinoma of the urinary bladder and 1149 controls in Spain; all the participants were white. We also carried out meta-analyses of NAT2, GSTM1, and bladder cancer that included more than twice as many cases as in previous reports. Findings: In our study, the odds ratios for bladder cancer for individuals with deletion of one or two copies of the GSTM1 gene were 1.2 (95% CI 0.8-1.7) and 1.9 (1.4-2.7) respectively (p for trend

UR - http://www.scopus.com/inward/record.url?scp=23844512858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844512858&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(05)67137-1

DO - 10.1016/S0140-6736(05)67137-1

M3 - Article

VL - 366

SP - 649

EP - 659

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9486

ER -